drugset / Trial / NCT00567879
A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab
NaSingle-groupOpen-labelTreatment
Summary
The primary purpose of this study is to identify the maximum tolerated dose (MTD) of both intravenous and oral panobinostat plus trastuzumab. The study will evaluate safety and efficacy of the combination in adult female patients with HER2+ metastatic breast cancer
Timeline
- Start
- 2008-04
- Primary completion
- 2011-05
- Completion
- 2011-05
Outcome
Outcome not reported
Stopped: “The study was terminated early due to insufficient evidence of clinical benefit.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Panobinostat | Small molecule | 10 mg/m2 | Intravenous |
| Subject | Panobinostat | Small molecule | 20 mg | Intravenous |
| Background | Trastuzumab | Monoclonal antibody | — | Intravenous |